COSMOS Pharmaceutical Corporation
TSE Prime
¥6,501.00
-1.29%
Delayed · cached 15 min
Fair value analysis
3349
COSMOS Pharmaceutical Corporation
¥6,501.00
Close used for this calculation
¥6,481.56Fair value
Financial DNA Score
Profitability · Returns · Balance Sheet · Efficiency · Growth
36/100
Quality radar
Consensus fair value
¥6,481.56
Near FV▼ -0.3% against the close used
Model range ¥1,277.12 – ¥9,086.59
The lowest and highest of the models that produced a value. This is the spread of the methods, not a price target.
Price target range & 52-week position
Bear¥1,277.12Fair value¥6,481.56Bull¥9,086.59
FairClose
52-week traded range
52W low ¥5,710.0052W high ¥9,088.00
The 52-week range is measured from the stored price history, not estimated.
Valuation summary
Trading close to the consensus fair value
COSMOS Pharmaceutical Corporation closed at ¥6,501.00, 0.3% above the consensus fair value of ¥6,481.56 drawn from 9 valuation models.
Financial DNA score 36/100 — Average. P/E of 16.1x against the 20x sector multiple the P/E model uses.
Quantitative summary only — not investment advice.
All valuation models
DCF Valuation
¥5,804.85
-10.7%
Σ[CF×(1+g)^n/(1.10)^n] + TV/(1.10)^10
g=3.4%, r=10%, tg=3%, n=10yr
Graham Number
¥5,700.51
-12.3%
√(22.5 × EPS × BVPS)
EPS=404.33, BVPS=3571.98 · outside Graham range (P/E 16.1, P/B 1.8) — asset-light, treat as a rough floor
P/E Fair Value
¥8,086.60
+24.4%
EPS × 20x (sector P/E)
EPS=404.33, Sector P/E=20x
Peter Lynch (PEG)
¥1,362.59
-79.0%
EPS × Growth% (PEG = 1 is fair)
EPS=404.33, g=3.4%
EV/EBITDA
¥9,086.59
+39.8%
(EBITDA × 11.7x − Net Debt) ÷ Shares
EBITDA=66.93B
Dividend Discount (DDM)
¥1,277.12
-80.4%
D1 ÷ (r − g) where D1 = D0×(1+g)
D0=81.91, r=10%, g=3.4%
Book Value (P/B)
¥4,541.75
-30.1%
BVPS × (ROE−g)÷(r−g) [Justified P/B — RIM-based]
BVPS=3571.98, ROE=11.8%, g=3.4%, r=10%
Reverse DCF
¥6,501.00
+0.0%
Solve for g: Price = Σ[EPS×(1+g)^n/(1.10)^n] + TV
Implied: 4.2% | Historical: 3.4%
Margin of Safety
¥4,897.99
-24.7%
Avg(DCF, Graham, P/E) × 75% (25% safety buffer)
Avg fair value=6530.65, MoS=25%
Computed on September 12, 2026 from the most recent annual report on file and that day's closing price. Where a company has seen its earnings move sharply since its last annual report, this figure will lag the market.
Educational data only. Not a recommendation to buy, sell or hold any security.